^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ILB-2109
i
Other names: ILB-2109, ILB2109, WTS-001
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Innolake Biopharma
Drug class:
Adenosine A2A receptor antagonist
Related drugs:
11d
A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
P1, N=48, Active, not recruiting, Innolake Biopharm | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2024 --> Dec 2024
Enrollment closed • Trial primary completion date • Metastases
|
ILB-2109
6ms
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=200, Recruiting, Innolake Biopharm | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule)
|
PD-L1 expression
|
Loqtorzi (toripalimab-tpzi) • ILB-2109
6ms
A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
P1, N=48, Recruiting, Innolake Biopharm | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Nov 2023 --> Aug 2024
Trial completion date • Trial primary completion date
|
ILB-2109
over1year
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=200, Not yet recruiting, Innolake Biopharm
New P1/2 trial • Metastases
|
Loqtorzi (toripalimab-tpzi) • ILB-2109
Share via
